Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15442285 | 1.00 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL13279217 | 1.00 | SMARCA2 (0.52) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL652991 | 0.88 | MEN1 (0.53) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL652990 | 0.88 | MEN1 (0.53) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL1409835 | 0.88 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL656085 | 0.88 | MEN1 (0.53) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL1409607 | 0.88 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL1409606 | 0.88 | SMARCA2 (0.53) | SMARCA2SMARCA4PBRM1GPR119LMNA | |
| SCHEMBL15858050 | 0.88 | GPR119 (0.48) | SMARCA2SMARCA4PBRM1GPR119ADAMTS5 | |
| SCHEMBL31112041 | 0.88 | GPR119 (0.48) | SMARCA2SMARCA4PBRM1GPR119LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697232-B1 | 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES | OTSUKA PHARMA CO LTD (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-5994356-A | ANTICOAGULANT | KARL THOMAE (DE) | 1999-11-30 | — | — | US | disclosed |
| EP-0892783-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | Dr. Karl Thomae GmbH (DE) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997037975-A1 | CARBOXYLIC ACID DERIVATIVES WITH AN AGGREGATION-INHIBITING ACTION | DR. KARL THOMAE GMBH (DE) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | SMARCA2 3763/4885SMARCA4 3880/4885PBRM1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.